TY - JOUR
T1 - Randomized evaluation of trial acceptability by INcentive (RETAIN)
T2 - Study protocol for two embedded randomized controlled trials
AU - Krutsinger, Dustin C.
AU - McMahon, Jacqueline
AU - Stephens-Shields, Alisa J.
AU - Bayes, Brian
AU - Brooks, Steven
AU - Hitsman, Brian L.
AU - Lubitz, Su Fen
AU - Reyes, Celine
AU - Schnoll, Robert A.
AU - Ryan Greysen, S.
AU - Mercede, Ashley
AU - Patel, Mitesh S.
AU - Reale, Catherine
AU - Barg, Fran
AU - Karlawish, Jason
AU - Polsky, Daniel
AU - Volpp, Kevin G.
AU - Halpern, Scott D.
N1 - Funding Information:
This work was supported by National Institutes of Health: National Cancer Institute grants numbered RO1CA197332 and 5RO1CA184211 . The funding source has no role in the study design, data collection, analytic plans or manuscript preparation.
Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2019/1
Y1 - 2019/1
N2 - Introduction: The most common and conceptually sound ethical concerns with financial incentives for research participation are that they may (1) represent undue inducements by blunting peoples' perceptions of research risks, thereby preventing fully informed consent; or (2) represent unjust inducements by encouraging enrollment preferentially among the poor. Neither of these concerns has been shown to manifest in studies testing the effects of incentives on decisions to participate in hypothetical randomized clinical trials (RCTs), but neither has been assessed in real RCTs. Methods and analyses: We are conducting randomized trials of real incentives embedded within two parent RCTs. In each of two trials conducted in parallel, we are randomizing 576 participants to one of three incentive groups. Following preliminary determination of patients' eligibility in the parent RCT, we assess patients' research attitudes, demographic characteristics, perceived research risks, time spent reviewing consent documents, ability to distinguish research from patient care, and comprehension of key trial features. These quantitative assessments will be supplemented by semi-structured interviews for a selected group of participants that more deeply explore patients' motivations for trial participation. The trials are each designed to have adequate power to rule out undue and unjust inducement. We are also exploring potential benefits of incentives, including possible increased attention to research risks and cost-effectiveness.
AB - Introduction: The most common and conceptually sound ethical concerns with financial incentives for research participation are that they may (1) represent undue inducements by blunting peoples' perceptions of research risks, thereby preventing fully informed consent; or (2) represent unjust inducements by encouraging enrollment preferentially among the poor. Neither of these concerns has been shown to manifest in studies testing the effects of incentives on decisions to participate in hypothetical randomized clinical trials (RCTs), but neither has been assessed in real RCTs. Methods and analyses: We are conducting randomized trials of real incentives embedded within two parent RCTs. In each of two trials conducted in parallel, we are randomizing 576 participants to one of three incentive groups. Following preliminary determination of patients' eligibility in the parent RCT, we assess patients' research attitudes, demographic characteristics, perceived research risks, time spent reviewing consent documents, ability to distinguish research from patient care, and comprehension of key trial features. These quantitative assessments will be supplemented by semi-structured interviews for a selected group of participants that more deeply explore patients' motivations for trial participation. The trials are each designed to have adequate power to rule out undue and unjust inducement. We are also exploring potential benefits of incentives, including possible increased attention to research risks and cost-effectiveness.
KW - Behavioral economics
KW - Ethics
KW - Incentives
KW - Nudge
KW - Randomized controlled trials
UR - http://www.scopus.com/inward/record.url?scp=85056585875&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056585875&partnerID=8YFLogxK
U2 - 10.1016/j.cct.2018.11.007
DO - 10.1016/j.cct.2018.11.007
M3 - Article
C2 - 30414865
AN - SCOPUS:85056585875
SN - 1551-7144
VL - 76
SP - 1
EP - 8
JO - Contemporary Clinical Trials
JF - Contemporary Clinical Trials
ER -